These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38862020)

  • 1. MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways.
    Wang L; Li L; Zhao D; Yuan H; Zhang H; Chen J; Pang D; Lu Y; Ouyang H
    Open Biol; 2024 Jun; 14(6):230427. PubMed ID: 38862020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural effects of the slow/b-cardiac myosin heavy chain R453C mutation in cardiac and skeletal muscle.
    Tajsharghi H; Fyhr IM
    Scand Cardiovasc J; 2008 Apr; 42(2):153-6. PubMed ID: 18365899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
    Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
    Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studying Pathogenetic Contribution of a Variant of Unknown Significance, p.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells.
    Pavlova SV; Shulgina AE; Zakian SM; Dementyeva EV
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy.
    Yang P; Lou Y; Geng Z; Guo Z; Wu S; Li Y; Song K; Shi T; Zhang S; Xiong J; Chen AF; Li D; Pu WT; Da L; Zhang Y; Sun K; Zhang B
    Circulation; 2024 Jul; 150(4):283-298. PubMed ID: 38752340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of
    Loiben AM; Chien WM; Friedman CE; Chao LS; Weber G; Goldstein A; Sniadecki NJ; Murry CE; Yang KC
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incomplete-penetrant hypertrophic cardiomyopathy
    Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. End-stage Hypertrophic Cardiomyopathy with Advanced Heart Failure in Patients Carrying MYH7 R453 Variants: A Case Series.
    Naito S; Higo S; Kameda S; Ogawa S; Tabata T; Akazawa Y; Nakamura D; Nakamoto K; Sera F; Kuramoto Y; Asano Y; Hikoso S; Miyagawa S; Sakata Y
    Intern Med; 2023 Nov; 62(21):3167-3173. PubMed ID: 36948619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrying both the heterozygous Myh6-R453C and Tnnt2-R92W mutations aggravate the hypertrophic cardiomyopathy phenotype in mice.
    Lu M; Li S; Han Z; Ma B; Wang L; Wan F; Lei S; Nie Y; Wang J
    Biochem Biophys Res Commun; 2024 Nov; 733():150582. PubMed ID: 39191188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful knock-in of Hypertrophic Cardiomyopathy-mutation R723G into the MYH7 gene mimics HCM pathology in pigs.
    Montag J; Petersen B; Flögel AK; Becker E; Lucas-Hahn A; Cost GJ; Mühlfeld C; Kraft T; Niemann H; Brenner B
    Sci Rep; 2018 Mar; 8(1):4786. PubMed ID: 29555974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYH7B variants cause hypertrophic cardiomyopathy by activating the CaMK-signaling pathway.
    Chen P; Li Z; Nie J; Wang H; Yu B; Wen Z; Sun Y; Shi X; Jin L; Wang DW
    Sci China Life Sci; 2020 Sep; 63(9):1347-1362. PubMed ID: 32207065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function.
    Sommese RF; Sung J; Nag S; Sutton S; Deacon JC; Choe E; Leinwand LA; Ruppel K; Spudich JA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12607-12. PubMed ID: 23798412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
    Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
    Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload.
    Schnelle M; Sawyer I; Anilkumar N; Mohamed BA; Richards DA; Toischer K; Zhang M; Catibog N; Sawyer G; Mongue-Din H; Schröder K; Hasenfuss G; Shah AM
    Cardiovasc Res; 2021 Jan; 117(1):178-187. PubMed ID: 31821410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic MYH7 expression regulation contributes to tissue level allelic imbalance in hypertrophic cardiomyopathy.
    Montag J; Syring M; Rose J; Weber AL; Ernstberger P; Mayer AK; Becker E; Keyser B; Dos Remedios C; Perrot A; van der Velden J; Francino A; Navarro-Lopez F; Ho CY; Brenner B; Kraft T
    J Muscle Res Cell Motil; 2017 Aug; 38(3-4):291-302. PubMed ID: 29101517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-β promote epithelial-mesenchymal transition via NF-κB/NOX4/ROS signal pathway in lung cancer cells.
    Ma M; Shi F; Zhai R; Wang H; Li K; Xu C; Yao W; Zhou F
    Mol Biol Rep; 2021 Mar; 48(3):2365-2375. PubMed ID: 33792826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertrophic cardiomyopathy: low frequency of mutations in the beta-myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients.
    García-Castro M; Reguero JR; Batalla A; Díaz-Molina B; González P; Alvarez V; Cortina A; Cubero GI; Coto E
    Clin Chem; 2003 Aug; 49(8):1279-85. PubMed ID: 12881443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.